Quazinone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Quazinone
Quazinone.svg
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
Synonyms Ro 13-6438
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C11H10ClN3O
Molar mass 235.67 g/mol
3D model (Jmol)

Quazinone (Dozonone) is a cardiotonic and vasodilator drug which was developed and marketed in the 1980s for the treatment of heart disease.[1][2][3][4][5] It acts as a selective PDE3 inhibitor.[6][7] It is no longer available.[1]

See also[edit]

References[edit]

  1. ^ a b David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9. 
  2. ^ Eigenmann R, Gerold M, Holck M (1984). "Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 511–9. PMID 6202980. doi:10.1097/00005344-198405000-00021. 
  3. ^ Holck M, Thorens S, Muggli R, Eigenmann R (1984). "Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 520–30. PMID 6202981. doi:10.1097/00005344-198405000-00022. 
  4. ^ Belz GG, Stern HC, Butzer R (1985). "Dose-response following single administrations of a new cardiac performance enhancer RO 13-6438 in normal volunteers". Journal of Cardiovascular Pharmacology. 7 (1): 86–90. PMID 2580156. doi:10.1097/00005344-198501000-00014. 
  5. ^ Daly PA, Chatterjee K, Viquerat CE, et al. (June 1985). "RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure". The American Journal of Cardiology. 55 (13 Pt 1): 1539–44. PMID 4003296. doi:10.1016/0002-9149(85)90969-5. 
  6. ^ Osinski MT, Schrör K (August 2000). "Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis". Biochemical Pharmacology. 60 (3): 381–7. PMID 10856433. doi:10.1016/S0006-2952(00)00328-2. 
  7. ^ Denis D, Riendeau D (February 1999). "Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes". European Journal of Pharmacology. 367 (2-3): 343–50. PMID 10079010. doi:10.1016/S0014-2999(98)00987-X.